PMI U.S. BRINGS TECHNOVATION TO WASHINGTON D.C.

Rhea-AI Summary

Philip Morris International (NYSE: PM) launches its Technovation science and innovation platform in the U.S. on April 14, 2026, convening scientists, policymakers and industry to accelerate a smoke-free future. PMI highlights investments in U.S. manufacturing (Aurora, Owensboro, Wilson) and a U.S. workforce > 3,000.

PMI reports its smoke-free business accounted for 41.5% of full‑year 2025 net revenues, and says it invested more than $16 billion since 2008 to develop smoke-free products used by over 43 million legal‑age consumers globally.

Positive

• Smoke-free revenue represented 41.5% of full‑year 2025 net revenues
• $16+ billion invested since 2008 in developing smoke‑free products
• U.S. workforce scaled to 3,000+ employees supporting domestic manufacturing

Negative

• None.

Key Figures

Smoke-free investment: $16 billion Smoke-free consumers: over 43 million Smoke-free revenue mix: 41.5% +5 more

8 metrics

Smoke-free investment $16 billion Invested since 2008 in smoke-free product development and commercialization (as of Dec 31, 2025)

Smoke-free consumers over 43 million Legal-age consumers using PMI smoke-free products worldwide as of Dec 31, 2025

Smoke-free revenue mix 41.5% Share of PMI full-year 2025 total net revenues from smoke-free products

Smoke-free markets over 105 markets Number of markets where PMI smoke-free products are available for sale

U.S. workforce more than 3,000 employees PMI U.S. workforce after scaling from several hundred employees in recent years

U.S. smokers target approximately 30 million Legal-age U.S. consumers who smoke cigarettes that PMI U.S. aims to serve with alternatives

Technovation date April 14 Date of Technovation’s one-day U.S. debut event in Washington, D.C.

Smoke-free business share 41.5% of net revenues Contribution of smoke-free business to PMI’s 2025 total net revenues

Market Reality Check

Price: $163.54 Vol: Volume 3,475,790 is below...

low vol

$163.54 Last Close

Volume Volume 3,475,790 is below the 20-day average of 5,191,016, suggesting a relatively muted pre-news session. low

Technical Shares trade below the 200-day MA of 166.65 with price at 163.54, indicating a still-soft longer-term trend.

Peers on Argus

PM was up 0.65% pre-news. Key peers BTI (+0.57%), MO (+2.28%), and KO (+1.19%) w...

PM was up 0.65% pre-news. Key peers BTI (+0.57%), MO (+2.28%), and KO (+1.19%) were also positive, while RLX fell 4.07%. With no names in the momentum scanner and mixed peer moves, trading appeared more stock-specific than a clear sector rotation.

Historical Context

5 past events · Latest: Mar 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 17	U.S. investment, jobs	Positive	-1.1%	Announced $50M Tampa Business Solutions Center creating about 180 high-skilled jobs.
Mar 09	Philanthropic donation	Positive	+1.9%	Provided $50,000 grant to support veteran mental-health and stabilization services.
Mar 05	Dividend declaration	Positive	-5.2%	Declared regular $1.47 quarterly dividend with smoke-free business metrics highlighted.
Mar 04	Community grant	Positive	+0.6%	Announced $150,000 grant to California Asian Pacific Chamber for small business programs.
Feb 18	Forecast reaffirmed	Positive	-0.5%	Reaffirmed 2026 EPS forecast and growth outlook at the CAGNY investor conference.

Pattern Detected

Recent news has mostly been positive, but price reactions were mixed, with several instances of selling or muted responses after favorable announcements.

Recent Company History

Over the last few months, Philip Morris International has highlighted investments in U.S. operations, community grants, and reaffirmed its 2026 EPS outlook, alongside a regular quarterly dividend of $1.47 per share. Smoke-free products and U.S. expansion have been recurring themes, with prior updates on U.S. investments and philanthropy. Market reactions have alternated between modest gains and declines, suggesting that even constructive news often met profit-taking or cautious sentiment ahead of this Technovation announcement.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-06

PMI has an effective automatic shelf registration on Form S-3ASR filed 2026-02-06, allowing issuance of debt securities and warrants to purchase debt securities from time to time for general corporate purposes. No usage has been recorded yet, with 0 prospectus supplements filed.

Market Pulse Summary

This announcement underscores PMI’s push to define the modern nicotine market through Technovation’s...

Analysis

This announcement underscores PMI’s push to define the modern nicotine market through Technovation’s U.S. debut and significant smoke-free investments exceeding $16 billion since 2008. It highlights that smoke-free products contributed 41.5% of 2025 net revenues and reach over 43 million adult consumers across more than 105 markets. Investors may watch how U.S. regulatory developments, adoption trends, and future updates on smoke-free revenue mix and volumes evolve following this platform launch.

Key Terms

nicotine pouch, heat-not-burn, e-vapor products, modified risk tobacco product, +3 more

7 terms

nicotine pouch medical

"including heat-not-burn, nicotine pouch and e-vapor products."

A nicotine pouch is a small, pre-portioned sachet containing nicotine and flavoring but no tobacco leaf; users tuck it between the lip and gum where nicotine is absorbed through the mouth. Think of it like a tiny tea bag that delivers nicotine without smoking. Investors watch this product because it represents a fast-growing alternative to cigarettes and vaping, affecting sales mix, regulation risk, public perception, and long-term profitability in the nicotine market.

heat-not-burn medical

"including heat-not-burn, nicotine pouch and e-vapor products."

A heat-not-burn product is a consumer device that warms processed tobacco or nicotine material to generate an inhalable aerosol without burning it, similar to how a hot plate steams food instead of frying it. Investors watch these products because they can change demand for traditional cigarettes, face distinct regulatory and legal risks, and influence long-term revenue and public perception in tobacco and nicotine markets.

e-vapor products medical

"including heat-not-burn, nicotine pouch and e-vapor products."

E-vapor products are battery-powered devices and the liquids or cartridges they use to produce an inhalable aerosol, including electronic cigarettes, vaporizers and related refill fluids. Think of them as small electronic appliances that heat flavored or nicotine-containing liquid so users can inhale vapor instead of smoke. Investors track them because sales, regulation, health concerns, taxes and public opinion can quickly change demand, liabilities and profit margins across manufacturers, retailers and suppliers.

modified risk tobacco product regulatory

"hold 80% of modified risk tobacco product (MRTP) authorizations"

A modified risk tobacco product is a tobacco or nicotine product that is marketed with claims it reduces health risks or exposure to harmful substances compared with other tobacco products; such claims are typically subject to regulatory review and approval. For investors, this matters because approved modified-risk status can change consumer demand, legal exposure, labeling requirements and market access—similar to how a government-backed “low-risk” label can alter a product’s sales and liability profile.

MRTP regulatory

"hold 80% of modified risk tobacco product (MRTP) authorizations"

An MRTP (Modified Risk Tobacco Product) is an official U.S. regulatory designation for a tobacco or nicotine product that a regulator has reviewed and allowed to be marketed as posing lower health risks or reduced exposure to harmful substances. Think of it like an official “lower-risk” label: investors watch MRTP decisions closely because they can open or restrict market access, change legal and marketing rights, and materially affect a product’s sales and a company’s valuation.

premarket tobacco product application regulatory

"and 41% of premarket tobacco product application (PMTA) marketing orders"

A premarket tobacco product application is the formal submission a company must file with regulators to get permission to market a new or significantly changed tobacco product. Think of it as a permit showing evidence that the product is acceptable for public health—companies must provide scientific data on ingredients, emissions and likely impact on users and non-users. Investors care because approval determines whether a product can be sold, affects revenue potential, regulatory risk and a company’s valuation.

PMTA regulatory

"and 41% of premarket tobacco product application (PMTA) marketing orders"

A Premarket Tobacco Product Application (PMTA) is a formal submission to a regulatory agency seeking permission to legally sell a new or changed tobacco or nicotine product. It lays out safety data, product design, and evidence that the product is appropriate for public health; approval is like a green light to enter the market. For investors, PMTA outcomes can make or break a company’s ability to sell products, affecting revenue forecasts and stock value, much like a building permit determines whether a construction project can proceed.

AI-generated analysis. Not financial advice.

PMI's global science and innovation platform brings together leaders to accelerate progress toward a smoke-free future

WASHINGTON, March 30, 2026 /PRNewswire/ -- Technovation, the global science and innovation platform of Philip Morris International (PMI) (NYSE: PM), will make its U.S. debut on April 14. The one-day event brings together experts, policymakers, scientists, media, and business leaders across the Americas to explore how innovation, science, and regulation can accelerate progress toward a smoke-free future.

The U.S. launch of Technovation marks a key moment for the platform and for the future of nicotine in the United States. A global leader in smoke-free innovation, PMI is advancing the development and adoption of smoke-free alternatives worldwide, helping millions of adults who smoke switch to better alternatives. In parallel, PMI and its U.S. businesses (PMI U.S.) are strongly committed to investing in America, making significant, long-term investments across U.S. manufacturing, infrastructure, and workforce development to support the growth of its smoke-free portfolio and strengthen domestic capabilities. This includes expanding its U.S. manufacturing footprint and investing in advanced production facilities in Aurora, Colorado; Owensboro, Kentucky; and Wilson, North Carolina, while growing a workforce that has scaled from several hundred employees to more than 3,000 in recent years.

Positioned at the nexus of science, innovation, and real-world adoption, PMI U.S. is defining the modern nicotine market in this country and accelerating the nation's smoke-free future. The business is focused on its smoke-free portfolio and anchored by ZYN, the nation's leading smoke-free product and first nicotine pouch authorized by the U.S. Food and Drug Administration (FDA).

The event will bring together leading voices across science, policy, and business to explore the forces shaping smoke-free products, from product innovation and regulatory progress to evolving consumer behaviors and preferences. It will debut new data on an often-overlooked segment of the U.S. adult smoking population, tackle persistent challenges such as misperceptions about nicotine and highlight the need for collaboration with law enforcement to help combat illicit trade. PMI will also feature an interactive exhibition with demonstrations and immersive experiences that showcase the science behind its portfolio of smoke-free products.

"Technovation is an important platform to better understand the scientific and technological progress behind today's smoke free alternatives," said Stacey Kennedy, Chief Executive Officer of PMI U.S. "Here in the United States, our business is focused on leading the smoke free future—investing in innovation, domestic manufacturing, and partnerships to responsibly develop smoke free products that meet the expectations of a highly regulated market and support a science based, responsible approach to modern nicotine."

Since 2008, PMI has invested more than $16 billion in developing, scientifically substantiating and commercializing smoke-free products (as of 31 December 2025), now used by over 43 million legal age consumers worldwide. Committed to responsible marketing practices and scientific integrity, PMI's affiliates hold 80% of modified risk tobacco product (MRTP) authorizations and 41% of premarket tobacco product application (PMTA) marketing orders issued by the U.S. FDA. The company also holds an extensive portfolio of patents supporting its smoke-free technologies and ambitions, underscoring its continued leadership in scientific advancement and product innovation.

PMI U.S.: Invested in America
Philip Morris International Inc.'s U.S. businesses are invested in America's future and advancing a smoke-free nation. The businesses are committed to providing the approximately 30 million legal-age consumers who smoke cigarettes with better, smoke-free alternatives and to ensuring the products are marketed responsibly. From PMI's global headquarters in Stamford, Connecticut, and other locations nationwide, PMI U.S. contributes leadership, jobs, investment, and innovation in the U.S. The U.S. businesses employ more than 3,000 people across America and operate product manufacturing facilities, including in Aurora, Colorado, Owensboro, Kentucky, and Wilson, North Carolina. For more information, please visit www.uspmi.com. 

References to "PMI" mean the Philip Morris International family of companies. "PMI U.S.," "we," "our," and "us" refer to one or more PMI U.S. businesses. 

Philip Morris International: A Global Smoke-Free Champion
Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. Our smoke-free products are available for sale in over 105 markets, and as of December 31, 2025, PMI estimates they were used by over 43 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 41.5% of PMI's full year 2025 total net revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas. References to "PMI", "we", "our" and "us" mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.

Forward-Looking and Cautionary Statements 
This press release contains projections of future results and goals and other forward-looking statements, including statements regarding business plans and strategies. Achievement of future results is subject to risks, uncertainties, and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

PMI's business risks include: marketing and regulatory restrictions that could reduce our competitiveness, disrupt our SFP commercialization efforts, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; excise tax increases and discriminatory tax structures; health concerns relating to the use of tobacco and other nicotine-containing products; litigation related to tobacco and/or nicotine products and intellectual property rights; intense competition; inability to anticipate changes in adult consumer preferences; use and reliance on third-parties; the adverse effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; geopolitical instability affecting international trade; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; continued decline of tax-paid cigarettes; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, sustained periods of elevated inflation, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; disruptions in the credit markets or changes to its credit ratings; recent and potential future tariffs imposed by the U.S. and other countries; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as product components for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful, in key markets or systemically, in its efforts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity; if there are prolonged disruptions of facilities used to produce its products; if it is unable to enter new markets or improve its margins through increased prices and productivity gains; if other market participants are more successful in their SFP commercialization efforts; if it is unable to attract and retain the best global talent; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our smoke-free products performance.

PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2025. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pmi-us-brings-technovation-to-washington-dc-302728519.html

SOURCE PMI US Corporate Services, Inc.

FAQ

What is Technovation and when will PMI (PM) debut it in the U.S.?

Technovation is PMI's global science and innovation platform debuting in the U.S. on April 14, 2026. According to the company, the one-day event will gather scientists, policymakers and business leaders to discuss smoke-free product innovation, regulation, and consumer adoption.

How much has Philip Morris International (PM) invested in smoke-free products?

PMI has invested more than $16 billion in smoke-free development since 2008. According to the company, this funding supports scientific assessment, clinical research and commercialization of smoke-free alternatives globally.

What portion of PMI's 2025 revenues came from smoke-free products (PM)?

Smoke-free products accounted for 41.5% of PMI's full-year 2025 net revenues. According to the company, this reflects continued growth of its smoke-free portfolio alongside existing cigarette products.

Which PMI smoke-free products have received U.S. FDA authorizations?

PMI affiliates hold FDA authorizations for ZYN nicotine pouches and versions of IQOS and General snus. According to the company, affiliates hold 80% of MRTP authorizations and 41% of PMTA marketing orders issued by the FDA.

What U.S. investments and manufacturing expansion did PMI (PM) disclose?

PMI cites expanded U.S. manufacturing in Aurora, Colorado; Owensboro, Kentucky; and Wilson, North Carolina. According to the company, these facilities and staffing support growth of its smoke-free product portfolio and domestic capabilities.